The roles of these TNFRSF1B SNVs in the outcomes of patients with lung cancer [29], non-Hodgkin lymphoma [30], and esophageal carcinoma [31] remain controversial, and their impacts on the outcomes of patients with CM are unknown. This evidence concerns the gene TNFRSF1B and cutaneous mastocytosis.